All In MedTech

Device Trial Radar · NCT02534571

To Compare a Hemostatic Powder TC-325 and Standard Treatment in the Control of Acute Upper Gastrointestinal Bleeding From Nonvariceal Causes

Endoscopic Application of a Hemostatic Powder TC-325 Versus Standard Treatment in the Control of Acute Upper Gastrointestinal Bleeding From Nonvariceal Causes; A Non-inferiority Randomized Trial

Last checked: Nov 19, 2026Latest source record: Oct 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 224 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

224

Actual

Start

Sep 7, 2015

Primary completion

Jan 14, 2019

Study completion Apr 30, 2019

Sponsor

Lead sponsor
Chinese University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
North District Hospital; King Chulalongkorn Memorial Hospital; Changi General Hospital
First posted
Aug 27, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute upper gastrointestinal bleeding is a common medical emergency. Bleeding peptic ulcers and other non-variceal causes constitute to about 95% of all cases of bleeding. Endoscopic treatment stops active bleeding, reduces rate of further bleeding and leads to improved patients outcomes. Endoscopic treatment can be technically demanding especially with lesions in difficult anatomic positions and to endoscopists with less experience. TC-325 is a propriety mineral blend hemostatic powder used to compress external civilian and military traumatic injuries. Investigators reported the first endoscopic application of TC-325 in 20 patients with actively bleeding gastro-duodenal ulcers. Investigators were able to stop bleeding in 19 of them. Subsequent case series from others reported a similar rate in the acute control of bleeding. To further define the role of TC-325 as a mono-therapy, a comparison to the current standard in endoscopic treatment is required. A non-inferiority randomized trial is being proposed to compare endoscopic use of TC-325 as a mono-therapy to current standards (i.e. hemoclips or thermo-coagulation with or without pre-injection with diluted epinephrine) in hemostatic treatment in patients with acute upper gastrointestinal bleeding from non-variceal causes. The non-inferiority primary endpoint is control of bleeding over 30 days from randomization. Other outcome endpoints include further endoscopic, angiographic or surgical treatments, hospitalization, blood transfusion and mortality. Investigators also compare ease of therapy measured by procedure time and a 10 cm visual analogue scale rated by endoscopists. Endoscopic application of TC-325 is a simple and less skill dependent technique. It may prove useful in bleeding from anatomically challenging sites of the gastro-duodenal tract.

Conditions

  • Acute Upper Gastrointestinal Bleeding

Interventions

  • Endoscopic Application of a Hemostatic Powder TC-325Device

    Endoscopic Application of a Hemostatic Powder TC-325 \<=150g once

  • Hemo-clippingDevice

    Hemo-clipping \<=20 clips

  • EpinephrineDrug

    epinephrine injection endoscopically \<20 mls

  • thermo-coagulationDevice

    contact thermo-coagulation \< = 4 pulses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. number of participants who presents and confirmed endoscopically as recurrent upper gastro-intestinal bleedingTime frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Endoscopy Centre

    Hong Kong, HONG KONG, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.